Details

Autor(en) / Beteiligte

• Sapp, John L
• Wells, George A
• Parkash, Ratika
• Stevenson, William G
• Blier, Louis
• Sarrazin, Jean-Francois
• Thibault, Bernard
• Rivard, Lena
• Gula, Lorne
• Leong-Sit, Peter
• Essebag, Vidal
• Nery, Pablo B
• Tung, Stanley K
• Raymond, Jean-Marc
• Sterns, Laurence D
• Veenhuyzen, George D
• Healey, Jeff S
• Redfearn, Damian
• Roux, Jean-Francois
• Tang, Anthony S.L

Titel

Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs

Ist Teil von

• The New England journal of medicine, 2016-07, Vol.375 (2), p.111-121

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2016

Link zum Volltext

Quelle

Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals

Beschreibungen/Notizen

• In patients with ischemic cardiomyopathy and an implantable cardioverter–defibrillator who had ventricular tachycardia, catheter ablation was associated with a lower rate of death, ventricular tachycardia storm, or ICD shock at 28 months than an escalation in antiarrhythmic drugs. Ventricular tachycardia caused by the scarring that occurs after myocardial infarction carries a substantial risk of death, a risk that is significantly reduced by the placement of an implantable cardioverter–defibrillator (ICD). 1 ICDs are implanted in more than 100,000 patients annually in the United States. Of these patients, 15% are initially treated with concomitant antiarrhythmic drug (AAD) therapy, 2 and up to 38% receive an appropriate shock for ventricular arrhythmia within 5 years. 3 ICDs effectively terminate ventricular tachycardia, but recurrent arrhythmias and ICD shocks may cause impairment in the quality of life, 4 are associated with an increased risk of death, heart failure, . . .